SAN MATEO, California. and TEL AVIVIsrael , June 21, 2022 /PRNewswire/ — KSM, the research and innovation center of Maccabi Health Services, of Israel leading HMO and ProgomiQ – a California-based healthcare company focused on harnessing the power of multi-omics data to transform detection, early treatment selection and surveillance of cancer and other complex diseases – today announced the launch of an innovative research collaboration. This partnership is focused on the discovery and development of dynamic cancer biomarkers utilizing KSM’s unique biobank (“Tipa Biobank™”), of Israel largest biobank for the early detection of colon, lung, pancreatic and breast cancer.
Maccabi’s Biobank, with its unique anonymized data sets and clinical expertise, together with PrognomiQ’s technology focused on extracting valuable biological insights from high-quality multi-omics data, will enable the creation of a biomarker platform that improves early detection intended , outcomes and care of cancer patients. PrognomiQ’s high-throughput, multi-omics approach enables large-scale trials and the development of highly sensitive assays for earlier cancer detection and cancer precision medicine, with the potential to save or significantly extend the lives of many more patients.
“Maccabi paves the way for innovative research to better model a comprehensive, multidimensional patient journey,” said Dr. Valley Patalon, head of KSM, Maccabi’s research and innovation center. “The intertwining of clinical disease progression with biological changes over time is key to a major breakthrough in disease redefinition and therefore personalization of treatment and prevention for each patient.”
“This collaboration with KSM is exciting because it involves a large number of biological samples that our high-throughput, multi-omics platform can interrogate for the development of novel disease detection assays in a variety of cancer types with high unmet needs, for earlier detection and treatment said Philip Ma, CEO of ProgomiQ. “PrognomiQ’s platform is unique in that it takes a next-generation approach to comprehensively probe the proteomic, metabolome, epigenome, transcriptome and genome for biomarkers – at scale, insights and novel biological content leading to transformative new approaches could lead to diagnostics and therapy development.”
The KSM Biobank is the largest biological bank in Israel, based on a nationwide population, and includes more than 800,000 biological anonymized samples. The Biobank is an unprecedented research resource that includes a re-sampling policy for the collection of participants throughout their lives. Through a database of biological samples, in compliance with regulations and privacy protection, it is possible to carry out a wide range of genetic and biological research, allowing for significant achievements and results for current and future research, in order to provide truly personalized healthcare in all areas – especially cancer.
About Kahn Sagol Maccabi (KSM)
Kahn-Sagol-Maccabi (KSM) is the research and innovation center of Maccabi Healthcare Services, of Israel leading HMO. KSM has unique access to Maccabi’s professional skills and medical knowledge, including a large database of 2.5 million members with 30 years of data collection. KSM’s activities across a wide range of healthcare areas impact patients worldwide across multiple areas. First, an innovation and big data space that leverages advanced data sources and AI technologies. Additionally KSM founded of Israel largest biobank with over 800,000 collected samples. KSM also operates a clinical research unit and a high-cost epidemiological research department. KSM leads advanced global health improvements, collaborating with renowned researchers, academic institutions, pharmaceutical companies, startups and technology companies to foster medical breakthroughs and collaborations within the global health ecosystem that enable breakthrough discoveries and solutions, and shape the future of health .
Founded in 2020, ProgomiQ is a healthcare company pioneering the development of multi-omics human testing for cancer and other complex diseases. In addition to metabolomics and genomics technologies, PrognomiQ also uses cutting-edge proteomics technologies to develop multi-omics products to improve human health.
View original content to download multimedia: https://www.prnewswire.com/news-releases/maccabis-ksm-research-and-innovation-center–prognomiq-announce-research-collaboration-aimed-at- early-cancer-detection-301571764.html